S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

LEGN Legend Biotech Corporation

46.02

0.00 (0.00%)

Pre Market

Last Updated: 18:00:59

Delayed by 15 minutes

Form 144/A - Report of proposed sale of securities: [Amend]

Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Jun 2024 to Jul 2024

Click Here for more Legend Biotech Charts.

Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Jul 2023 to Jul 2024

Click Here for more Legend Biotech Charts.

Legend Biotech Corporation News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Tuesday 4 June 2024 (4 weeks ago) • Edgar (US Regulatory)

Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
Tuesday 4 June 2024 (4 weeks ago) • Business Wire

Legend Biotech to Participate in the Jefferies Global Healthcare Conference
Wednesday 29 May 2024 (1 month ago) • Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Friday 24 May 2024 (1 month ago) • Edgar (US Regulatory)

Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
Friday 24 May 2024 (1 month ago) • Business Wire

U.S. Futures Climb Amid High Expectations for Inflation Data; Global Markets Show Mixed Reactions
Monday 13 May 2024 (2 months ago) • IH Market News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 13 May 2024 (2 months ago) • Edgar (US Regulatory)

Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
Monday 13 May 2024 (2 months ago) • Business Wire

CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Tuesday 23 April 2024 (2 months ago) • Business Wire

Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
Thursday 11 April 2024 (3 months ago) • Business Wire

Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
Saturday 6 April 2024 (3 months ago) • Business Wire

Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
Tuesday 19 March 2024 (3 months ago) • Business Wire

More Legend Biotech Corporation News Articles

Westpac Banking

Australian SE All Ordina...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions